Article information
Full text is only aviable in PDF
Bibliografía
[1.]
D.D. Sin, N.R. Anthonisen, J.B. Soriano, A.G. Agustí.
Mortality in COPD: role of comorbidities.
Eur Respir J, 28 (2006), pp. 1245-1257
[2.]
W.M. Chatila, B.M. Thomashow, O.A. Minai, G.J. Criner, B.J. Make.
Comorbidities in chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 5 (2008), pp. 549-555
[3.]
R. Rodriguez Roisin, J.B. Soriano.
Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease.
Proc Am Thorac Soc, 5 (2008), pp. 842-847
[4.]
L.M. Fabbri, F. Luppi, B. Beghé, K.F. Rabe.
Complex chronic comorbidities of COPD.
Eur Respir J, 31 (2008), pp. 204-212
[5.]
Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD 2008. [Consultado el 10-7-2009] Disponible en: http://www.goldcopd.org
[6.]
G. Peces-Barba, J.A. Barberà, A. Agustí, C. Casanova, A. Casas, J.L. Izquierdo, et al.
Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC.
Arch Bronconeumol, 5 (2008), pp. 271-281
[7.]
J. De Miguel Díez, M. Méndez Bailón.
Comorbilidad en la EPOC. Implicaciones diagnósticas y terapéuticas.
Rev Patol Respir, 11 (2008), pp. 109-116
[8.]
D.M. Mannino, G. Watt, D. Hole, C. Gillis, C. Hart, A. McConnachie, et al.
The natural history of chronic obstructive pulmonary disease.
Eur Respir J, 27 (2006), pp. 627-643
[9.]
P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, P.W. Jones, et al.
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
N Engl J Med, 356 (2007), pp. 775-789
[10.]
G. Bale, Camblor Martínez, P.S. Burge, J.B. Soriano.
Long-term mortality follow-up of the Isolde participants: causes of death during 13 years after trial completion.
Respir Med, 102 (2008), pp. 1468-1472
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
